Challenges and Opportunities in Cancer Detection and Diagnosis: The Need for Systems-Based Approaches For Successful Validation of Biomarkers

Dr. George Poste
Chief Scientist, Complex Adaptive Systems Initiative and Del E. Webb Chair in Health Innovation
Arizona State University
george.poste@asu.edu
www.casi.asu.edu

NCI Cancer Early Detection Stakeholders Meeting
Rockville, 21 May 2010
The Cancer Challenge: The Imperative to Achieve Earlier Detection and Diagnosis

- poor short-term prospect for truncation of extended 10-15 year R&D cycle times for new drugs
- unsustainable cost of Rx therapy with current outcomes
- high failure of investigational drugs in clinical trials
- testing of investigational Rx on late-stage patients with advanced refractory disease

- clinical, economic and social value of innovation in biomarker discovery and validation will increase
Disease-Associated Biomarkers: A Key Driver in the Future Healthcare Value Chain

- detection and diagnostic classification
- staging and progression
- prognosis
- prediction of Rx response and/or adverse event(s)
- novel Rx target ID and investigational drug optimization
- profile patient populations for enrichment/adaptive clinical trial design
- surrogate markers for disease risk, disease status monitoring and Rx efficacy
- functional analysis of signaling networks
Adoption of New Technologies Demands a ‘Systems’ Approach to Life Cycle Analysis (LCA)

- discovery
- translation and validation
  - technical, clinical, regulatory
- demonstrating value
  - clinical, patients, payors, society
- incentives for investment/adoptions
  - clinical utility
  - reimbursement
  - IP
Adoption of New Technologies Demands a ‘Systems’ Approach to Life Cycle Analysis (LCA)

- discovery
- translation and validation
  - technical, clinical, regulatory
- demonstrating value
  - clinical, patients, payors, society
- incentives for investment/adoptions
  - clinical utility
  - reimbursement
  - IP

• IMPROVED CLINICAL AND PATIENT OUTCOMES
Biomarker R&D
Building An Integrated Framework

**Discovery**
- candidate marker(s)
- biobanks
- sample standardization
- sample preparation
- high sensitivity analytical tools
  - immunoassays
  - arrays
  - MS
  - SERS
  - AFM
  - electrochemistry
- IP

**Validation**
- retrospective/prospective evaluation
- statistical power (large N)
- sample selection
- platform selection
- algorithms for multiplex tests
- data formatting for clinical use
- information transfer for remote monitoring
- data security

**Regulatory Review**
- unianalyte or multianalyte
- home brew/ASR
- 510 (K) or full review
  - IVDMIA
  - algorithms
  - platform
  - scope of clinical claims use
  - central lab.
  - hospital
  - POC/physician office
  - home
  - remote monitoring

**Validated**
- clinical utility
- value proposition
- CMS and CPT Coding
- co-use services
- promotion
- peer reviewed publications
Biomarker Discovery, Validation and Adoption: The Obligate Need for ‘Systems-Based’ Approaches

- samples
- signatures
- scale
- standards
Identification and Validation of Disease-Associated Biomarkers: Obligate Need for a Systems-Based Approaches

Biospecimens and Molecular Pathway Analysis

Biomarker Validation and Multiplex Assays

Instrumentation and Informatics

Clinical Impact and Patient Monitoring
# Molecular Diagnostics and Miniaturized Devices: A Key Future Driver in the Healthcare Value Chain

## Complex Biosignature Profiling

<table>
<thead>
<tr>
<th>genomics</th>
<th>proteomics</th>
<th>immunosignatures</th>
</tr>
</thead>
</table>

## Signature Detection, Deconvolution and Multivariate Analysis

- automated, high throughput multiplex assays
- novel test formats and devices (POC)
- new algorithms for complex signal/deconvolution
Trends in Mapping Diagnostic Signatures of Health and Disease

- unianalyte
- simple analytical endpoint(s)
- technician dependent
- centralized laboratory
- population-based reference index
- multiplex
- complex analytical algorithms
- high throughput automation
- lab-on-a-chip
- remote fault-diagnostics/repair
- migration to POC
- wireless remote monitoring
- individualized profile and longitudinal person record as reference index
• evaluation of test sample of 20 purified proteins at 5 pmole equimolar abundance
• 7/27 labs with initial correct characterization
• raw data from all sufficient to identify full 20 protein catalog and 22 derivative 1250 Da peptides
• diverse and poorly standardized databases and search engines as principal sources of erroneous reporting
  – variation in curation, annotation, comprehensiveness

• real world challenges: high complexity samples and large preanalytical (collection/storage) sample variation
• education and training to use complex technologies
• publication standards, formats and open-source dbases
• 7892 citations
• 46.4% also categorized search term ‘cancer’
Disease-Associated Biomarkers and Validation of Novel Molecular Diagnostics

- Literature dominated by anecdotal studies
  - academic laboratories
  - small patient cohorts
  - poor replication and confirmatory studies
- Lack of standardization
- Very few biomarkers subjected to rigorous validation
  - case-control studies with sufficient statistical power
  - inadequate stringency in clinical phenotyping
- Lack of understanding of regulatory requirements in academic research community
  - complexities imposed by multiplex tests
  - new regulatory oversight (IVDMIAs)
Development of Companion Diagnostics and Dx Test Validation Standard

- ODAC rejection (3/2010) of Omapro for Gleevec-resistant CML due to T315I mutation

- failure to use single standardized assay for all patients
  - peripheral blood versus bone marrow
  - 1/3 tested locally; 2/3 tested centrally
  - centralized labs used different assays with 100 fold sensitivity difference for the mutation
disease related differences are small compared to biological variability
many variables behave as QTLs with graded continuum rather than binary normal: disease separation
the high dimensionality small sample size (HDSS) problem
  - high number of variables (2000-10000) and low sample size (10-100)
  - increased risk of selection of variables due to chance (overfitting)
standardization and statistical powering
  - “the 20:200:2000 rule”
new regulatory complexities for multiplex ‘signatures’ as next-generation diagnostic tests/biomarkers
“We may be lost, but we’re having a good time”

Yogi Berra
The Cancer Biomarker Challenge

Samples
The Widespread Failure to Set Standards for Analysis and Annotation in Biomedical Research and Clinical Medicine

- Predominant analysis of poorly characterized tissue samples of convenience and statistically sub-powered studies
- Uniform QC/QA standards for sample acquisition, curation, annotation plus requisite statistical rigor
- Inadequate clinical stringency in patient ‘phenotyping’ and poorly standardized criteria for patient staging, progression and outcomes
- Consistent protocols for patient stratification and longitudinal case records for correlation of molecular pathology with clinical outcomes
Access to Quality Biospecimens for Medical Research

Ease of Acquiring Quality Biospecimens

- Difficult/Very difficult: 48%
- Somewhat difficult: 32%
- Somewhat easy: 13%
- Very easy/Easy: 8%

Question Their Data Because of the Quality of Biospecimens

- Never/Rarely: 40%
- Sometimes: 40%
- Often/Acways: 20%

Limit Research Scope of Work Due to the Shortage of Quality Biospecimens

- Never/Rarely: 19%
- Sometimes: 36%
- Often/Acways: 45%

http://biospecimens.cancer.gov/cahub/
Utility of Cancer Biospecimens for Biomarker Analysis

- ex vivo hematopoietic samples
- established cell lines
- xenografts
- blood/body fluids
- CTC
- fresh tissue
- fixed tissue

information content

Dynamic profiling of signaling networks

high

low
A Global Map of Human Gene Expression

- 5372 microarray samples
- 206 different laboratories
- 163 different laboratories
- 369 ‘groups’
  - cell or tissues type, disease state or cell line
- gene expression matrix of 14,000 genes X5372

http://www.ebi.ac.uk/gxa/array/U133A
• principal component analysis of 5372 microarray datasets from 369 cell lineages/tissues/lines
• consistent segregation patterns
• solid tissue cell lines cluster together rather than with respective tissues of origin
  – 1217 genes upregulated in all cell lines
  – cell cycle, division and mitosis genes
• neoplasm samples cluster as intermediate group between homologous normal tissue and immortalized cell lines
Challenging Questions

- Are the phenotypes and molecular pathways of cell lines and 2D cell cultures so unrepresentative of the situation to render them irrelevant and pose blind avenues for diagnostic/therapeutic discovery?
- Can the biology of metastasis be elucidated by analysis of non-metastatic cells?
- Should research on biomarkers for diagnosis, staging and Rx responsiveness be funded without demonstrated access to standardized samples and disease: control cohorts and/or prospective RCT samples of requisite statistical power?
Challenges Associated With Legacy Biobanks

- highly variable storage, curation and clinical annotation
- investigator/institutional ‘terroriality’
- ambiguous and varied informed consent provisions
  - disease specific versus blanket ‘research use’
- limited longitudinal sampling and correlation with clinical outcomes
- relative absence of normal tissue cohorts
Challenges in Establishing Rigorous Correlations Between Perturbations in Molecular Pathways and Disease

- more stringent criteria for clinical phenotyping
- obtaining the right phenotypes in the right quantity
- obtaining enough investigators with the right training and right resources
- right funding mechanisms to support the right studies
Reagents Data Portal

The Reagents Data Portal serves as a central source of reagents and resources made available by the CPTC initiative for the scientific community to support protein/peptide measurement and analysis efforts. This invaluable resource has been developed to advance proteomics research platforms for the prevention, early detection and treatment of cancer.

The Reagents Data Portal is in the process of expansion as the initiative makes way for numerous reagents and resources in the pipeline that are greatly needed for effective proteomic analysis.
Building Large Scale, Standardized Research and Clinical Resources for Efficient Translational Research

- common multisite protocols (HIPAA, IRB)
- biorepositories
- ‘omics’ assay formats
- integrated ‘omics’ datasets
- more stringent clinical phenotyping schemes and databases
- novel algorithms
  - scale
  - non-linear dynamics
- transparent regulatory standards
Translation of the Major Potential of Molecular Medicine into Routine Clinical Practice

A Complex Multi-Dimensional Challenge
The Real World

- innovation in science and technology alone is necessary but not sufficient
- adoption requires overcoming multiple barriers
  - existing competition/standard of care
  - cultural conservatism
  - reimbursement and other financial obstacles
  - regulatory hurdles
  - threat of IP protection
- wide variation in adoption speed by different sectors
  - healthcare (10-30 years)
  - computing (1-2 years)
  - engineering (1-10 years)
Standards for ‘Omics’ Data
Cross-Domain Integration,
Open-Source Data Sharing
and
Computational Analysis
Semantics:
The Need for Adoption of Standardized Taxonomies and Ontologies in Biomedical Research

- transcending the taxonomic anarchy of descriptive biology and medicine
- standardized nomenclature for biological systems
- reporting formats for quantitative data
- crucial foundation of productive assembly and analysis of large scale and open-source datasets
- facile integration of scientific and clinical data for evidence-based treatment selection/decision-analysis
The Rise of Open-Source Networks and Consortia

- NCBI
- Entrez, The Life Sciences Search Engine
- caBIG
- Cancer Biomedical Informatics Grid
- ALLEN INSTITUTE for BRAIN SCIENCE | Allen Brain Atlas
- W3C WORLD WIDE WEB consortium
- PubMed
- The Neurocommons
- CRITICAL PATH INSTITUTE
- Improving the Path for Innovative Therapies
- Genes, Environment and Health Initiative (GEI)
- The Cancer Genome Atlas
- Welcome to HuGENet
- Broad Institute
- Diabetes Genetics Initiative
- PGRN
- Creative Commons
- The Biomarkers Consortium
- Clinical Semantics Group
The Imperative for New Approaches: The Launch of Important New Strategic Programs
"Managing Mega-Data"

volume

scale

global networks

multiscale heterogeneity

integration
Mining The Data Deluge

- liberate intelligence from multiple source formats
- interoperability challenges
  - early discovery (chaos) vs. clinical trials (CDISC)
    vs. healthcare (HL7, SNOMED)
  - urgent imperative for methodological, ontology and data storage format standards
Setting Regulatory Standards for Multiplex IVDs

**FDA**
- MicroArray Quarterly Control (MAQC) Project
  - generation of RNA standards for transcriptomic assays
- Statement for Reporting Studies of Diagnostic Accuracy (STARD)
- FDA Data Template
- In Vitro Diagnostics Multivariate Index Assays (IVDMIAs)

**NIST**
- External RNA Controls Consortium (ERCC)
  - ‘spike’ panel of RNAs for transcriptomic assays
Regulatory Issues

- greater technical complexity of multianalyte IVD tests
  - clinical validation of claimed correlation with disease stratification/progression and/or Rx outcomes
  - stringency of sample curation and case clinical phenotyping for control cohort
  - size, cost and time of clinical validation trials
- validation of algorithms used in test interpretation/clinical decision (FDA)
  - statistical and mathematical methods “obscure to the requesting physician”
  - probabilistic versus absolute endpoints
- jurisdictional oversight authority (FDA/CMS)
Current Payor Value Propositions Do Not Align with Clinical/Economic Value of Molecular Diagnostics

The Imperative for Value-Based Pricing versus Current Cost-Based Models

- inadequate US Medicare coding and payment mechanisms
  - out moded, out-dated, lacking in transparency, inconsistently applied

- inappropriate assignment of existing CPT codes to new MDx tests

- engagement of third party payers who derive economic/clinical value from new MDx
The Perceived Value of Evidence for Coverage Determinations by Order of Significance

- BCBSA, Hayes, Kaiser Approval
- coverage in other plans
- inclusion in clinical guidelines of a major Association or College
  - discrepancy among guidelines, e.g. mammography
  - perceived rigor of the Association or College
  - agenda of Association or College
- peer review clinical journals
- FDA approval
- CLIA approval
Genes and Intellectual Property

14 March 2000

5 February 2010 Report

29 March 2010 SDNY Court Decision

16 April 2010 WSJ Editorial
Scale: Organizational and Cultural Challenges

- analytical silos: the curse of systems analysis
- entrenched historical tenets of increasingly specialized disciplines, subdisciplines and reductionism
- institutional reinforcement of fragmented approaches to complex multi-dimensional problems
  - academic departments and P&T criteria
  - funding mechanisms and study sections
- the imperative to build new capabilities in inter- and cross-disciplinary research

BIG SCIENCE
Facile Formats for Imaging Data

- samples
- signatures
- scale
- standards

- silos
- status quo
- sociology
Point: Hypotheses first

There is little to show for all the time and money invested in genomic studies of cancer, says Robert Weinberg — and the approach is undermining tried-and-tested ways of doing, and of building, science.

Counterpoint: Data first

Large, unbiased genomic surveys are taking cancer therapeutics in directions that could never have been predicted by traditional molecular biology, says Todd Golub.
Standards: Relevance

- discarding biologically and/or clinically irrelevant research methods/strategies
- insidious cultural and organizational barriers to change
  - propagation of funding for historical conceptual paradigms and experimental models despite evidence of low productivity
  - inadequate mechanisms for review/funding of ambitious cross-disciplinary programs
  - abundant evidence of shortcomings in many cell/animal systems as predictive models for human cancer
  - pressure for continued publication/funding sustains irrelevant models
Translational Medicine

- inadequate feedback loops from bench to bedside
- information gap in academia on complexity and rigor of preclinical / clinical / regulatory processes
- insufficient research-oriented clinicians
- competitiveness of AMCs and logistical and financial barriers to large scale trials and uniform protocols
- cultural challenges of launching projects with directed goals in academic communities with traditionally more autonomous behaviors and dominant individual investigator mentality/reward
- escalating ‘knowledge gap’ for healthcare professionals as a barrier that threatens traditional role as informed authority and decision-maker
<table>
<thead>
<tr>
<th>Changing the Sociology of Life Sciences and Clinical Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>● transcending silo mentalities, organization and funding</td>
</tr>
<tr>
<td>● rebalance public funding priorities to address scale and complexity of trans-disciplinary projects</td>
</tr>
<tr>
<td>● set new balance between hypothesis-driven and data-driven research</td>
</tr>
<tr>
<td>● poorly standardized, fragmented data</td>
</tr>
<tr>
<td>● the challenge of translational research: “the valley of dearth”</td>
</tr>
<tr>
<td>● cross-disciplinary initiatives and new career incentives/rewards</td>
</tr>
<tr>
<td>● new funding vehicles with suitable scale</td>
</tr>
<tr>
<td>● new review systems</td>
</tr>
<tr>
<td>● recognize importance and intellectual merits of large scale database assembly, curation, analysis</td>
</tr>
<tr>
<td>● standardized ontologies, consortia, grids, open source databases for meta-analyses</td>
</tr>
<tr>
<td>● stringent funding criteria for obligate assembly of full expertise spectrum</td>
</tr>
<tr>
<td>● new clinical training/ medical curriculum</td>
</tr>
<tr>
<td>● private: public partnerships</td>
</tr>
</tbody>
</table>
Forging the Complex Interactions Required to Build a Productive Translational Medical Research Capacity

- greater recognition of value and participation in pre-competitive, open-source networks/consortia
  - drive standards
  - defray risk
  - broaden partnerships
- more proactive role in shaping new trans-disciplinary education/training/employment opportunities
  - translational medicine
  - large scale database analytics
  - new analytics/models for non-linear dynamics in complex systems
  - health economics outcomes/systems modeling

Industry
Forging the Complex Interactions Required to Build a Productive Translational Medical Research Capacity

The Sociology of Biomedical Research and Clinical Medicine

- courage
  - to declare that major change is needed versus safe refuge of status quo
- disruptive change is never easy
  - active engagement will impose great demands without immediate short-term benefit(s) to individuals/institutions
- public expectancy, accountability and accomplishments
Forging the Complex Interactions Required to Build a Productive Translational Medical Research Capacity

The Sociology of Biomedical Research and Clinical Medicine

- **courage**
  - to declare that major change is needed versus safe refuge of status quo
- **disruptive change is never easy**
  - active engagement will impose great demands without immediate short-term benefit(s) to individuals/institutions
- **public expectancy, accountability and accomplishments**

Molecular Diagnostics and Imaging Technologies Can Transform Cancer Detection and Outcomes